×
About 19,470 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,454 results

Therapeutic approach and outcome of children with Philadelphia chromosome-positive acut...
https://doi.org/10.1002/pbc.29441
Pediatric Blood & Cancer; Aubert L, Petit A et. al.

Dec 3rd, 2021 - Since the introduction of tyrosine kinase inhibitors (TKIs), the profile of pediatric relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has changed. However, the management of pediatric Ph+ ALL relapses is not curr...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Dec 3rd, 2021 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children wit...
https://doi.org/10.1002/pbc.29496
Pediatric Blood & Cancer; El Amrousy D, El-Afify D et. al.

Nov 30th, 2021 - Omega 3 polyunsaturated fatty acids are dietary factors with several beneficial cardiovascular effects. This study aimed to assess the possible protective effect of omega 3 fatty acids on early doxorubicin-induced cardiac toxicity in children with...

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
https://clinicaltrials.gov/ct2/show/NCT02614066

Nov 29th, 2021 - Bridging therapy could be administered at the discretion of the investigator and is recommended for participants with high disease burden at baseline (M3 marrow [> 25% leukemic blasts] or ≥ 1,000 blasts/mm^3 in the peripheral circulation) to contr...

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03739814

Nov 29th, 2021 - PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia...

see more →

Guidelines  3 results

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  117 results see all →

Clinicaltrials.gov  321 results

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Dec 3rd, 2021 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
https://clinicaltrials.gov/ct2/show/NCT02614066

Nov 29th, 2021 - Bridging therapy could be administered at the discretion of the investigator and is recommended for participants with high disease burden at baseline (M3 marrow [> 25% leukemic blasts] or ≥ 1,000 blasts/mm^3 in the peripheral circulation) to contr...

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03739814

Nov 29th, 2021 - PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Nov 24th, 2021 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Nov 24th, 2021 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

see more →

News  890 results

Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T
https://www.medpagetoday.com/hematologyoncology/leukemia/95947

Dec 1st, 2021 - Next-generation sequencing-based detection of minimal residual disease (NGS-MRD) was highly predictive for the risk of relapse in children or young adults with acute lymphoblastic leukemia (ALL) after treatment with the chimeric antigen receptor (...

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL
https://www.onclive.com/view/treatment-landscape-shifts-away-from-chemotherapy-toward-targeted-approaches-in-all

Nov 22nd, 2021 - Traditional cytotoxic chemotherapy-containing regimens have been the backbone of treatment for adults with acute lymphoblastic leukemia (ALL) for decades. Common complications of traditional chemotherapy can be fatal and include infection, bleedin...

Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies
https://www.onclive.com/view/mortality-rate-associated-with-covid-19-breakthrough-cases-remains-high-in-hematologic-malignancies

Nov 18th, 2021 - Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available, according to preliminary dat...

Venetoclax heralded a new class of small-molecule blood cancer drugs
https://www.mdedge.com/hematology-oncology/article/248650/cll/venetoclax-heralded-new-class-small-molecule-blood-cancer
Walter Alexander

Nov 15th, 2021 - Venetoclax’s regulatory approvals, its success as monotherapy for chronic lymphocytic leukemia (CLL) and other lymphoid neoplasms, and its activity in combination against acute myeloid leukemia (AML) have helped pave the way for BCL2 and MCL1 inhi.

A Bigger Red Flag for CAR-T's Toll on the Heart, Lungs
https://www.medpagetoday.com/hematologyoncology/hematology/95248

Oct 25th, 2021 - Stronger signals of cardiovascular and pulmonary risk emerged in the largest postmarketing study of chimeric antigen receptor (CAR) T-cell therapy to date. In the FDA Adverse Event Reporting System (FAERS), the 2,657 patient reports for axicabtage...

see more →

Patient Education  3 results see all →